Library Assignment: Community Health Problem Paper

Type 2 Diabetes Mellitus: A Community Health Crisis and the Role of the Family Nurse Practitioner in Evidence-Based Primary Care

Introduction

Type 2 diabetes mellitus (T2DM) represents one of the most significant public health challenges of the twenty-first century, affecting millions of individuals across the globe and placing an immense burden on healthcare systems, families, and communities. As an advanced practice registered nurse, the Family Nurse Practitioner (FNP) occupies a unique and critical position at the intersection of individual patient care and population health management. FNPs are often the first point of contact for patients seeking primary care services, making them ideally situated to identify, manage, and prevent chronic conditions such as T2DM. This paper will examine T2DM as a community health problem, exploring its pathophysiology, risk factors, and clinical management from an evidence-based FNP perspective. Additionally, this analysis will address the social determinants of health that contribute to disparities in T2DM prevalence and outcomes, propose culturally appropriate interventions, and emphasize the essential role of the FNP in improving community health through the integration of current clinical guidelines and evidence-based practice.

Identification of the Community Health Problem

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction, leading to hyperglycemia and a cascade of microvascular and macrovascular complications. According to the International Diabetes Federation, the estimated global prevalence of diabetes in 2024 was 11.1%, corresponding to approximately 589 million adults aged 20–79 years, with projections indicating a rise to 13% (approximately 853 million) by 2050 due to increased urbanization and aging populations. Notably, 95% of this increase is expected to occur in low-to-middle-income countries, where population growth is predicted to outpace that of high-income nations. In the United States, T2DM remains a major public health challenge, particularly in the east south central regions, where disparities are pronounced. The condition is disproportionately concentrated among minoritized populations, including certain racial and ethnic groups, migrant populations, and rural communities, driven by longstanding structural and social inequities.

The significance of T2DM as a community health problem extends beyond its prevalence to encompass its substantial morbidity, mortality, and economic costs. The condition is a leading cause of cardiovascular disease, chronic kidney disease, blindness, and lower-extremity amputations, and it is associated with premature mortality. Furthermore, the economic burden of diabetes is staggering, encompassing direct medical costs, lost productivity, and reduced quality of life. The FNP practicing in a community setting must recognize that T2DM is not merely a clinical condition but a complex public health issue shaped by behavioral, socioeconomic, and environmental factors that require comprehensive, multisectoral interventions.

Advanced Clinical Application

From a pathophysiological perspective, T2DM arises from a combination of insulin resistance in peripheral tissues (muscle, liver, and adipose tissue) and relative insulin deficiency due to impaired pancreatic beta-cell function. The development of insulin resistance is closely linked to obesity, particularly visceral adiposity, which promotes the release of pro-inflammatory adipokines and free fatty acids that interfere with insulin signaling pathways. Over time, the compensatory hyperinsulinemia that initially maintains euglycemia becomes insufficient as beta-cells undergo progressive failure, leading to overt hyperglycemia. The clinical presentation of T2DM can be insidious, with many patients remaining asymptomatic for years. Common symptoms include polyuria, polydipsia, polyphagia, unexplained weight loss, fatigue, and blurred vision. However, a significant proportion of individuals with T2DM are diagnosed incidentally during routine laboratory testing or when they present with complications such as cardiovascular events, infections, or non-healing wounds.

Key risk factors for T2DM include age, obesity, physical inactivity, family history, ethnicity (with higher prevalence among African American, Hispanic/Latino, Native American, and Asian American populations), history of gestational diabetes, polycystic ovary syndrome, and certain medications such as steroids and antipsychotics. The American Diabetes Association (ADA) recommends screening for prediabetes and diabetes in all adults beginning at age 35, or earlier in individuals with overweight or obesity and one or more additional risk factors. Prediabetes is defined clinically as a glycated hemoglobin (HbA1c) level of 42–47 mmol/mol (6.0–6.4%) or a fasting plasma glucose level of 6.1–6.9 mmol/L.

From the FNP perspective, the diagnostic evaluation of a patient with suspected T2DM should include a comprehensive history and physical examination, assessment of cardiovascular risk factors, and appropriate laboratory testing, including HbA1c, fasting plasma glucose, lipid panel, and renal function tests. Management strategies must be individualized and encompass both pharmacologic and non-pharmacologic interventions. The 2025 ADA Standards of Care emphasize a person-first, inclusive approach to diabetes care, with treatment goals tailored to the individual’s preferences, values, and clinical circumstances. Pharmacologic management typically begins with metformin as first-line therapy, although the 2025 International Diabetes Federation guidelines note that initial combination therapy can achieve early glycemic control with increased durability compared to stepwise addition of glucose-lowering drugs. For patients with established cardiovascular disease, chronic kidney disease, or high cardiovascular risk, sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended for their cardiovascular-kidney protective benefits. Non-pharmacologic management, including medical nutrition therapy, physical activity, and weight management, remains the foundation of T2DM care.

Evidence-Based Practice Integration

Evidence-based practice is the cornerstone of high-quality primary care, and the FNP must integrate current clinical guidelines and peer-reviewed research into clinical decision-making for patients with T2DM. The Scottish Intercollegiate Guidelines Network (SIGN) published a comprehensive guideline in 2025 on the prevention and remission of type 2 diabetes, providing recommendations on prevention, early detection, and early non-pharmacological and pharmacological treatment to reduce diabetes risk. This guideline recommends that primary care healthcare professionals implement a two-stage strategy to identify people at high risk of type 2 diabetes, utilizing validated risk assessment tools such as QDIABETES-18.

A systematic review published in 2025 examined the effectiveness of lifestyle interventions in managing type 2 diabetes in primary care settings and found that structured lifestyle programs incorporating multidisciplinary teams and technology led to improvements in HbA1c, weight, blood pressure, and cholesterol. Similarly, a community-based nutrition education intervention conducted in a low-resource primary care setting demonstrated significant improvements in glycated hemoglobin (from 8.4% to 7.9%) and blood pressure, underscoring the value of culturally tailored interventions.

The 2025 International Diabetes Federation guidelines recognize global disparities in healthcare access and propose two standards of care—’optimal care’ and ‘basic care’—with both emphasizing good glycemic control to prevent complications. Key messages from these guidelines include the importance of early glycemic control using conventional glucose-lowering drugs to prevent complications and preserve quality of life, multifactorial management using effective glucose-lowering drugs and organ-protective agents, individualized regimens with shared decision-making, and the recognition that metformin is a foundation therapy. The FNP must critically appraise this evidence and apply it to the unique circumstances of each patient, recognizing that clinical guidelines provide a framework but must be adapted to the individual’s preferences, values, and social context.

Community and Population Health Implications

Social determinants of health (SDOH) play a profound role in shaping T2DM risk, prevalence, and outcomes. Recent research has demonstrated that food insecurity, smoking, poverty, lack of health insurance, and neighborhood characteristics are significantly associated with higher T2DM prevalence. A study investigating multilevel determinants of T2DM in the east south central United States found that food insecurity, smoking, poverty, the percentage of uninsured individuals, and the percentage of Black residents were significantly associated with higher diabetes prevalence. Furthermore, significant interactions were observed between obesity and physical inactivity, and between obesity and social deprivation, indicating that the association between obesity and diabetes prevalence varies according to behavioral and socioeconomic conditions. These findings highlight the combined influence of behavioral, socioeconomic, and environmental factors in shaping regional diabetes disparities and underscore the need for targeted public health interventions.

The FNP must recognize that providing culturally competent care is not sufficient to address these disparities; rather, cultural safety requires a critical examination of one’s own biases, assumptions, and the impact of power and privilege on healthcare delivery. This involves acknowledging that patients from marginalized communities may have experienced discrimination, mistrust, and barriers to care that influence their health behaviors and engagement with the healthcare system. The FNP can address these issues by building trust, using plain language and teach-back methods to ensure understanding, providing translated materials and interpreter services, and respecting diverse cultural beliefs about health, diet, and medication. Furthermore, the FNP should advocate for community-based interventions that address the root causes of diabetes disparities, such as food insecurity, lack of access to safe spaces for physical activity, and inadequate health insurance coverage.

Evidence-based, culturally appropriate interventions for T2DM prevention and management in primary care include lifestyle modification programs that promote weight loss of 5-10% of body weight, structured dietary interventions, and increased physical activity. The FNP should also collaborate with community partners, such as food banks, faith-based organizations, and public health departments, to create environments that support healthy behaviors. Additionally, the FNP can implement screening programs to identify individuals at high risk for T2DM and refer them to diabetes prevention programs, which have been shown to reduce the incidence of diabetes by nearly 60% in high-risk individuals. Patient education should emphasize the importance of self-management, including blood glucose monitoring, medication adherence, foot care, and recognition of signs and symptoms of complications. Finally, the FNP must address the mental health needs of patients with T2DM, as depression and diabetes distress are common and can adversely affect glycemic control and quality of life.

Conclusion

Type 2 diabetes mellitus is a complex and multifaceted community health problem that requires a comprehensive, evidence-based, and culturally sensitive approach to prevention and management. The Family Nurse Practitioner is uniquely positioned to lead these efforts, integrating clinical expertise with population health strategies to improve outcomes for individuals, families, and communities affected by this chronic condition. By applying current clinical guidelines, addressing social determinants of health, and engaging in culturally safe practice, the FNP can reduce diabetes-related disparities and promote health equity. The evidence is clear: early detection, lifestyle modification, appropriate pharmacotherapy, and patient-centered care can significantly reduce the burden of T2DM and its devastating complications. As frontline primary care providers, FNPs must embrace their role as advocates, educators, and clinicians, working collaboratively with patients, communities, and interdisciplinary teams to transform the trajectory of this epidemic. The challenge is immense, but the opportunity to make a meaningful difference in the lives of those affected by T2DM is equally profound.

References

American Diabetes Association Professional Practice Committee. (2025). Introduction and methodology: Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement_1), S1–S5. https://doi.org/10.2337/dc25-SINT[reference:23]

Ahmadi, F., et al. (2025). Where you live shapes diabetes risk: Multilevel determinants of type 2 diabetes in the East South Central United States. Journal of Racial and Ethnic Health Disparities. Advance online publication. https://doi.org/10.1007/s40615-026-03110-y[reference:24]

International Diabetes Federation. (2025). Glycaemic control remains central in type 2 diabetes mellitus management: Key learnings from the latest International Diabetes Federation guidelines. Diabetes Research and Clinical Practice. https://doi.org/10.1016/j.diabres.2026.112392[reference:25]

National Institute for Health and Care Excellence. (2025). Type 2 diabetes in adults: Management (Draft guideline GID-NG10336). https://www.nice.org.uk[reference:26]

Scottish Intercollegiate Guidelines Network. (2025). Prevention and remission of type 2 diabetes (SIGN Publication No. 172). https://www.sign.ac.uk[reference:27]